Summary
4SC AG (4SC) is a biopharmaceutical company that discovers and develops small molecule drugs for the treatment of cancer and autoimmune diseases. The company’s product focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its product pipeline comprises therapeutic programs at various stages of clinical development and early-stage research projects including resminostat, 4SC-202, and 4SC-208. The company’s research programs are related to cancer stem cells, ion channel blockers and cytokine modulation. It develops and markets products through partnerships with pharmaceutical and biotech companies. The company operates through its subsidiary 4SC Discovery GmbH. 4SC is headquartered in Bayern, Germany.
4SC AG (VSC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
4SC AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
4SC AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
4SC AG, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
4SC Discovery Enters Into Collaboration with Heidelberg University Hospital 13
AiCuris Enters Into Drug Discovery Agreement With 4SC Discovery And Crelux 13
UCB Enters Into Drug Discovery Agreement With Crelux And 4SC Discovery 14
LEO Pharma Enters Into Research Agreement With 4SC For Inflammatory Skin Diseases 15
4SC Discovery Enters Into Research Agreement With Biontech 16
4SC Plans To Enters Into Co-Development Agreement For Resminostat 17
4SC Enters Into Co-Development Agreement With Crelux And Ribological 18
4SC Plans To Enter Into Co-Development Agreement With A Pharma Company 19
Licensing Agreements 19
Maruho Enters into Licensing Agreement with 4SC 19
Link Health Enters into Licensing Agreement with 4SC 20
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 21
4SC Discovery Enters Into Licensing Agreement With BioNTech For TLR Agonists 22
4SC Expands Licensing Agreement With ViroLogik For VL-01 23
4SC Plans Licensing Agreement For Vidofludimus 24
4SC Enters Into Licensing Agreement With Yakult Honsha For Resminostat 25
Equity Offering 26
4SC Raises USD46 Million in Rights Offering of Shares 26
4SC Raises USD32 Million in Rights Offering of Shares 27
4SC Completes Private Placement For US$16.17 Million 28
Debt Offering 29
4SC Raises USD0.6 Million in Second Tranche of Private Placement of Notes 29
Asset Transactions 30
Immunic Acquires Immunology Portfolio from 4SC 30
Panoptes Pharma Acquires Patents To Treat Eye Diseases From 4SC Discovery 31
Acquisition 32
BioNTech Small Molecules Acquires 4SC Discovery from 4SC 32
4SC AG - Key Competitors 33
Key Employees 34
Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Nov 10, 2016: 4SC provides Q3 2016 update 36
Aug 11, 2016: 4SC provides operational and financial update for Q2 and 6M 2016 38
Mar 30, 2016: 4SC announces results for financial year 2015 39
Corporate Communications 41
Oct 21, 2016: 4SC: Dr Daniel Vitt to step down as CDO/CSO and from the Management Board at the End of 2016 41
Sep 21, 2016: Dr Jason Loveridge appointed new CEO of 4SC 42
Government and Public Interest 43
May 12, 2016: 4SC reports on key events in Q1 2016 43
Product Approvals 45
Feb 24, 2016: FDA approves IND application for resminostat in liver cancer 45
Clinical Trials 46
May 27, 2016: 4SC provides headline results from Yakult Honsha’s Phase II trial of resminostat in combination with sorafenib as first line therapy in liver cancer 46
Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48
List of Tables
4SC AG, Pharmaceuticals & Healthcare, Key Facts, 2016 1
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
4SC AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
4SC AG, Deals By Therapy Area, 2011 to YTD 2017 9
4SC AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
4SC Discovery Enters Into Collaboration with Heidelberg University Hospital 13
AiCuris Enters Into Drug Discovery Agreement With 4SC Discovery And Crelux 13
UCB Enters Into Drug Discovery Agreement With Crelux And 4SC Discovery 14
LEO Pharma Enters Into Research Agreement With 4SC For Inflammatory Skin Diseases 15
4SC Discovery Enters Into Research Agreement With Biontech 16
4SC Plans To Enters Into Co-Development Agreement For Resminostat 17
4SC Enters Into Co-Development Agreement With Crelux And Ribological 18
4SC Plans To Enter Into Co-Development Agreement With A Pharma Company 19
Maruho Enters into Licensing Agreement with 4SC 19
Link Health Enters into Licensing Agreement with 4SC 20
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 21
4SC Discovery Enters Into Licensing Agreement With BioNTech For TLR Agonists 22
4SC Expands Licensing Agreement With ViroLogik For VL-01 23
4SC Plans Licensing Agreement For Vidofludimus 24
4SC Enters Into Licensing Agreement With Yakult Honsha For Resminostat 25
4SC Raises USD46 Million in Rights Offering of Shares 26
4SC Raises USD32 Million in Rights Offering of Shares 27
4SC Completes Private Placement For US$16.17 Million 28
4SC Raises USD0.6 Million in Second Tranche of Private Placement of Notes 29
Immunic Acquires Immunology Portfolio from 4SC 30
Panoptes Pharma Acquires Patents To Treat Eye Diseases From 4SC Discovery 31
BioNTech Small Molecules Acquires 4SC Discovery from 4SC 32
4SC AG, Key Competitors 33
4SC AG, Key Employees 34
4SC AG, Subsidiaries 35
List of Figures
4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
